YZ-35 是一种 STAT3 抑制剂(Ki 值为 0.38 μM),能以高亲和力直接结合 STAT3(解离常数 Kd 为 190 nM),直接抑制 STAT3 在 Tyr705 和 Ser727 位点的双重磷酸化,抑制乳腺癌细胞系的菌落形成与细胞迁移并诱导细胞凋亡 (apoptosis),选择性抑制乳腺癌干细胞 (BCSC) 的自我更新能力,并在乳腺癌干细胞异种移植模型中抑制肿瘤生长,可用于乳腺癌研究。
YZ-35
产品编号: MS-I10419 分子式: C29H24N2O5S 分子量: 512.58
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

YZ-35 是一种 STAT3 抑制剂(Ki 值为 0.38 μM),能以高亲和力直接结合 STAT3(解离常数 Kd 为 190 nM),直接抑制 STAT3 在 Tyr705 和 Ser727 位点的双重磷酸化,抑制乳腺癌细胞系的菌落形成与细胞迁移并诱导细胞凋亡 (apoptosis),选择性抑制乳腺癌干细胞 (BCSC) 的自我更新能力,并在乳腺癌干细胞异种移植模型中抑制肿瘤生长,可用于乳腺癌研究。

生物实验数据

生物活性 YZ-35 is a STAT3 inhibitor with a Ki of 0.38 μM that directly binds STAT3 with high affinity (dissociation constant Kd = 190 nM), directly inhibits dual phosphorylation of STAT3 at Tyr705 and Ser727, suppresses colony formation and cell migration and induces apoptosis (apoptosis) in breast cancer cell lines, selectively inhibits the self-renewal capacity of breast cancer stem cells (BCSCs), inhibits tumor growth in breast cancer stem cell xenograft models, and can be used for breast cancer research.
体外研究
(In Vitro)

YZ-35 (0.1-100 μM, 48 h) 对 MDA-MB-231 细胞 (IC50 = 0.63 μM), MCF-7 细胞 (IC50 = 0.32 μM) 和 MCF-10A 细胞 (IC50 = 34.34 μM) 显示出抑制效力。
YZ-35 (0-4 μM, 0-48 h) 通过直接减弱 STAT3 的双重磷酸化 (Tyr705 和 Ser727),在 MDA-MB-231 和 MCF-7 细胞中表现出强效的抗乳腺癌功效。
YZ-35 (0-6 μM, 24-48 h) 抑制 MDA-MB-231 和 MCF-7 细胞的集落形成、细胞迁移并诱导细胞凋亡。
YZ-35 (2.5-10 μM, 48 h) 降低 MDA-MB-231 和 MCF-7 细胞的肿瘤干性。

Cell Viability Assay

Cell Line: MDA-MB-231 cells, MCF-7 cells and MCF-10A cells
Concentration: 0.1-100 μM
Incubation Time: 48 h
Result: Demonstrated inhibitory potency against MDA-MB-231 cells (IC50 = 0.63 μM), MCF-7 cells (IC50 = 0.32 μM) and MCF-10A cells (IC50 = 34.34 μM).

Western Blot Analysis

Cell Line: MDA-MB-231 cells and MCF-7 cells
Concentration: 0, 1, 2, 3, 4 μM
Incubation Time: 0, 12, 24, 36, 48 h
Result: Exhibited concentration- and time-dependent suppression of the phosphorylation of STAT3 at both Tyr705 and Ser727 residues in MDA-MB-231 and MCF-7 cell lines, while maintaining total STAT3 protein levels.
Showed no effect on the expression levels of STAT1 and STAT5 or their phosphorylation.
Did not impact the phosphorylation of JAK2, Src, and ERK.
Inhibited the expression of critical apoptosis-related proteins, including Cyclin D1, BCL2, BCL-xL, and Survivin, in a concentration-dependent manner.

Cell Migration Assay

Cell Line: MDA-MB-231 cells and MCF-7 cells
Concentration: 0, 1, 2, 3 μM
Incubation Time: 24 h
Result: Decreased the migration of MDA-MB-231 cells by 99%.
Reduced the migration in MCF-7 cells by 72.97%.

Apoptosis Analysis

Cell Line: MDA-MB-231 cells and MCF-7 cells
Concentration: 0, 1, 2, 4, 6 μM
Incubation Time: 48 h
Result: Induced programmed cell apoptosis in a concentration-dependent manner, with differential responses observed between BRCA subtypes: predominantly late-stage apoptosis in MDA-MB-231 cells, while promoting both earlyand late-phase apoptotic events in MCF-7 cells.

Immunofluorescence

Cell Line: MDA-MB-231 cells and MCF-7 cells
Concentration: 0, 1, 2, 3 μM
Incubation Time: 48 h
Result: Induced programmed cell death of BRCA, notably manifesting as pronounced chromatin condensation and nuclear fragmentation, with the most substantial apoptotic phenotype observed at 3 μM concentration.
体内研究
(In Vivo)

YZ-35 (5-10 mg/kg,静脉给药,每日一次,持续 21 天) 抑制 BCSC 异种移植模型中的肿瘤生长。

Animal Model: 1 × 107 MDA-MB-21 cells were resuspended with 100 μL saline and injected into the left flank of 5-week-old female BALB/c-nude mice
Dosage: 5, 10 mg/kg
Administration: i.v. once daily for 21 days
Result: Inhibited tumor growth (the TGI of high (10 mg/kg) and low (5 mg/kg) groups were 89.98 and 74.13%, respectively).
Inhibited STAT3 phosphorylation and significantly reduced FOXM1 and AURKA expression.
Augmented the proportion of apoptotic cells while concurrently diminishing Ki67-positive proliferating cell populations in tumor tissues relative to vehicle controls.
Showed no significant toxicity was observed in major organs including the heart, liver, spleen, lung, and kidney.

化学信息

分子量 512.58
分子式 C29H24N2O5S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础